Impact of Posttreatment SPECT/CT on Patient Management During 177Lu-PSMA-617 Radiopharmaceutical Therapy, published in Journal of Nuclear Medicine, the study revealed that nearly 50% of patients experienced a change in management based on posttreatment SPECT/CT. In 28% of cases, disease progression was detected, leading to treatment discontinuation, while 20% showed response leading to treatment pauses. This is a cost-effective imaging approach to closely monitor disease progression with each radiopharmaceutical therapy (RPT) cycle. 

The research was published by first author Surekha Yadav, MD, with Blair Lowrey, MD, Abuzar Moradi Tuchayi, MD, Rachelle Saelee, Roxanna Juarez, MD, Rob Flavell, MD, PhD, and senior author Tom Hope, MD.

Yadav emphasizes the potential impact on patient care, “Integrating posttreatment SPECT/CT into the routine PSMA RPT workflow can streamline personalized patient management by serving as a response marker to RPT.’’